Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (12): 732-736.doi: 10.3760/cma.j.cn371439-20200419-00110

• Reviews • Previous Articles     Next Articles

Correlation between CXCR1 and malignant tumors

Liu Yanquan, Shen Jianzhen()   

  1. Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Department of Hematopathology, Fujian Medical University Union Hospital, Fuzhou 350001, China
  • Received:2020-04-19 Revised:2020-05-18 Online:2020-12-08 Published:2021-01-28
  • Contact: Shen Jianzhen E-mail:doctorsjz@163.com
  • Supported by:
    Joints Funds for the Innovation of Science and Technology of Fujian Province(2018Y9010);Health and Family Planning Research Personnel Training Program of Fujian Province(2016-ZQN-29);Health and Family Planning Research Personnel Training Program of Fujian Province(2018-ZQN-40)

Abstract:

As an important member of the G protein coupled receptor superfamily, CXC chemokine receptor 1 (CXCR1) is also one of the most important and affinity receptors for CXC chemokine interleukin 8. CXCR1 is often expressed on the surface of cells such as neutrophils, monocytes and T cells, which can bind to CXC chemokine ligand (CXCL)6, CXCL7 and CXCL8. Studies have found that CXCR1 plays a vital role in promoting the metastasis, chemotherapy resistance and maintaining the characteristics of tumor stem cells. Down-regulating the expression of CXCR1 can significantly inhibit the biological characteristics of malignant tumors. At present, the academic field regards CXCR1 as the proto-oncogene of malignant tumors. CXCR1 is expected to become a potential target for the diagnosis and treatment of malignant tumors.

Key words: Receptors, chemokine, Receptors, interleukin-8A, Chemokines, CXC, Neoplasms